At a glance
1
Finished Products
1
Therapy Areas
1+
Delivery Formats
C3-CURA™
Primary Platform
All ingredients
Ingredient · 12/14
Ingredient · 12/14Myo-Inositol
myo-Inositol (1,2,3,4,5,6-hexol)
myo-Inositol (1,2,3,4,5,6-hexol)
Market Landscape
The opportunity – and where the market falls short.
- 01Metabolic regulator – insulin sensitivity, glucose metabolism, hormonal balance
- 02Women's health focus – PCOS, fertility, menstrual regulation
- 03Multi-dimensional benefits – reproductive, metabolic, mental health
- 04High-growth segment in women's health
- 05Sachet-dominated with limited format innovation
The Stabicon Edge
From market limitation to measurable transformation.
| Market Limitation | Stabicon Transformation | Impact |
|---|---|---|
| Format Limitation | Multi-Format & Convenient Delivery | Beyond sachets and powders |
| Compliance Issues | Enhanced Taste & Easy Formats | Better adherence |
| Low Differentiation | Intelligent Combinations (NAC, Zinc, Vitamin D3) | Outcome-driven formulations |
| Narrow Positioning | Condition-Specific Design – PCOS, fertility, hormonal balance | Expanded clinical relevance |
| Lack of Delivery Innovation | Optimized Ratios & Dosing | Clinically aligned formulations |
| Underutilized Potential | Expanded Use Cases – metabolic health, mood support | Broader women's health platform |
Stabicon's Portfolio
Myo-Inositol reimagined across therapy areas and delivery formats.
1 finished formulation powered by Myo-Inositol, organised across 1 therapy category.
01
Products
01
Therapy Areas
01+
Formats
01 · PCOS • Menstrual • Postpartum • Endometriosis
Translate